Skip to main content
VALIRX PLC logo

VALIRX PLC — Investor Relations & Filings

Ticker · VAL ISIN · GB00BLH13C52 LEI · 213800VQKB9SJCQDET40 IL Professional, scientific and technical activities
Open in API
Filings indexed 574 across all filing types
Latest filing 2016-11-29 Earnings Release
Country GB United Kingdom
Listing IL VAL

About VALIRX PLC

https://www.valirx.com/

ValiRx PLC is a life science company that accelerates the development of therapeutics and diagnostics, with a primary focus on oncology and women's health. The company's business model centers on identifying and progressing promising early-stage scientific discoveries through pre-clinical and clinical development. ValiRx provides scientific, financial, and commercial expertise to translate novel research into clinically validated treatments, aiming to improve patient outcomes in its target therapeutic areas.

Recent filings

Filing Released Lang Actions
Quarterly Update on Clinical Developments
Earnings Release Classification · 1% confidence The document is titled 'QUARTERLY UPDATE ON CLINICAL DEVELOPMENTS' and provides detailed progress reports on two clinical compounds (VAL201 and VAL401), including Phase I/II trial status, safety data (DLT, SAE), patient enrollment, and patent updates. This content strongly aligns with the description of an Interim/Quarterly Report (IR), which covers comprehensive financial or operational results for a period shorter than a year. Although it is an update, its depth suggests it is more than just a brief Earnings Release (ER) or a simple announcement of a report (RPA). The presence of 'RNS Number' and the closing 'This information is provided by RNS' indicates it was distributed via the Regulatory News Service, but the content itself is a substantive quarterly operational update, making 'IR' the most appropriate classification over the general 'RNS' fallback. Q4 2016
2016-11-29 English
ValiSeek Clinical Development Update
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and is dated '03 November 2016'. The content is a press release titled 'VALISEEK CLINICAL DEVELOPMENT UPDATE' providing an update on a clinical trial (VAL401-001) for a drug. It details patient progress, safety monitoring, and future presentation plans. The document concludes with contact information and boilerplate 'About' sections, ending with 'This information is provided by RNS The company news service from the London Stock Exchange'. This structure is characteristic of a general regulatory announcement disseminated via the London Stock Exchange's Regulatory News Service (RNS). Since it is not a full financial report (10-K, IR), a specific management change (MANG), or a dividend notice (DIV), the most appropriate classification is the general regulatory filing category.
2016-11-03 English
Patent Update
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and is dated October 25, 2016. The content announces specific corporate updates regarding patent grants for therapeutic compounds (VAL201 and VAL401) and mentions that the announcement 'is inside information for the purposes of Article 7 of Regulation 596/2014.' The document concludes with 'This information is provided by RNS The company news service from the London Stock Exchange' and an 'END' marker. This structure is characteristic of a general regulatory news service announcement, which fits the definition of Regulatory Filings (RNS) as a miscellaneous or general regulatory announcement, especially since it doesn't fit the more specific categories like ER, IR, or CAP.
2016-10-25 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is a 'TR-1: Notification of Major Interest in Shares' form, which is the standard regulatory filing used in the UK to disclose when a shareholder's interest in a company crosses specific voting rights thresholds. The document explicitly identifies the issuer (ValiRx PLC) and the entities subject to the notification (Yorkville Advisors Global, et al.). This fits the definition of a 'Major Shareholding Notification' (MRQ).
2016-10-13 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is clearly identified by the header 'RNS Number : 4973M' and the footer 'This information is provided by RNS The company news service from the London Stock Exchange'. The content details a 'TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES', specifically reporting changes in voting rights and share ownership thresholds (crossing 11.00%). This type of mandatory disclosure regarding significant changes in shareholding is classified as a Major Shareholding Notification (MRQ) under the provided definitions, as it directly relates to changes in significant ownership levels crossing thresholds. Although it is distributed via RNS, the specific content maps best to MRQ.
2016-10-13 English
Result of General Meeting
AGM Information Classification · 1% confidence The document is explicitly marked with an 'RNS Number' and concludes with 'This information is provided by RNS The company news service from the London Stock Exchange'. The content announces the 'RESULT OF GENERAL MEETING' where all resolutions were passed. While it relates to a General Meeting, the primary function of this specific document is to serve as a regulatory news service announcement detailing the outcome of a vote/meeting, rather than being the AGM presentation (AGM-R) or the proxy solicitation material (PSI). Since it is a general regulatory announcement disseminated via RNS that doesn't fit perfectly into the other specific categories (like DVA, which is for official voting results, though this is related), the most appropriate classification based on the source identifier and nature as a broad regulatory update is RNS.
2016-10-12 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.